-

The Law Offices of Frank R. Cruz Announces Investigation of Fluor Corporation (FLR) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Fluor Corporation (“Fluor” or the “Company”) (NYSE: FLR) concerning whether the board breached its fiduciary duties to shareholders.

If you are a shareholder, click HERE to participate.

On August 1, 2025, Fluor released its second quarter 2025 financial results, missing consensus estimates, citing growing costs in multiple infrastructure projects due to subcontractor design errors, price increases, and scheduling delays, as well as reduced capital spending by customers. The Company also lowered its full year 2025 outlook due to “client hesitation around economic uncertainty and its impact on new awards and project delays and results for the quarter[.]”

On this news, Fluor’s stock price fell $15.35, or 27%, to close at $41.42 per share on August 1, 2025, thereby injuring investors.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you still hold Fluor shares purchased before February 2025 and wish to discuss this matter with us, or have any questions concerning your rights and interests with regards to this matter, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 2121 Avenue of the Stars, Suite 800, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
fcruz@frankcruzlaw.com
www.frankcruzlaw.com

The Law Offices of Frank R. Cruz

NYSE:FLR

Release Versions

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
fcruz@frankcruzlaw.com
www.frankcruzlaw.com

More News From The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz Announces Investigation of Inspire Medical Systems, Inc. (INSP) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Inspire Medical Systems, Inc. (“Inspire” or the “Company”) (NYSE: INSP) concerning whether the board breached its fiduciary duties to shareholders. If you are a shareholder, click HERE to participate. On August 4, 2025, Inspire disclosed that the launch of its new sleep apnea device, the Inspire V, was facing an “elongated timeframe” due to several issues, including...

The Law Offices of Frank R. Cruz Announces Investigation of Stride, Inc. (LRN) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Stride, Inc. (“Stride” or the “Company”) (NYSE: LRN) concerning whether the board breached its fiduciary duties to shareholders. If you are a shareholder, click HERE to participate. On September 14, 2025, Simply Wall St. published a report stating that the Gallup-McKinley County Schools Board of Education had filed a complaint against Stride, alleging fraud, decepti...

The Law Offices of Frank R. Cruz Announces Investigation of Cytokinetics, Incorporated (CYTK) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) concerning whether the board breached its fiduciary duties to shareholders. If you are a shareholder, click HERE to participate. On May 1, 2025, Cytokinetics disclosed that the FDA has extended the review period for its cardiac myosin inhibitor drug, aficamten, by three months, citing additi...
Back to Newsroom